Absolute Diagnostics advanced Fluorescence Polarization Immunoassay (FPIA) UDT panels test for residues of 50 common pain management drugs followed by testing utilizing LC-MS/MS technology Mass Spectrometers for critical analysis, elimination of false negatives and best-in-class sensitivity.
Clinically, the benefits of FPIA UDT followed by mass spectrometry are multiple. These include reducing the risk for toxicity in patients vulnerable to adverse drug effects, avoidance of medico-legal problems, detecting patient non-compliance, reducing the risk of therapeutic failure, and avoiding or detecting drug-drug interaction. Additionally, mass spectrometry can confirm the presence of a prescribed drug from a UDT and to identify drugs not included in the screening test. The test is capable of detecting drugs and metabolites that may show a negative result during screening such as the synthetic and semisynthetic opioids.